Back to Search
Start Over
The role of ghrelin signalling in second-generation antipsychotic-induced weight gain.
- Source :
-
Psychoneuroendocrinology . Nov2013, Vol. 38 Issue 11, p2423-2438. 16p. - Publication Year :
- 2013
-
Abstract
- Summary: Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of SGAs; followed by a secondary decrease possibly due to the negative feedback from the SGA-induced body weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. Moreover, the results can also vary depending on individual SGAs, other hormonal states, dietary choices, and other confounding factors including medical history, co-treatments, age, gender, and ghrelin measurement techniques. Interestingly, rats treated with olanzapine, an SGA with high weight gain liabilities, are associated with increased hypothalamic ghrelin receptor (GHS-R1a) levels. In addition, expressions of downstream ghrelin signalling parameters at the hypothalamus, including neuropeptide Y (NPY)/agouti-related peptide (AgRP) and proopiomelanocortin (POMC) are also altered under SGA treatments. Thus, understanding the role of ghrelin signalling in antipsychotic drug-induced weight gain should offer potential novel pharmacological targets for tackling the obesity side-effect of SGAs and its associated metabolic syndrome. [Copyright &y& Elsevier]
Details
- Language :
- English
- ISSN :
- 03064530
- Volume :
- 38
- Issue :
- 11
- Database :
- Academic Search Index
- Journal :
- Psychoneuroendocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 91601708
- Full Text :
- https://doi.org/10.1016/j.psyneuen.2013.07.010